WADA monitors GLP-1 drugs for potential sport misuse

The World Anti-Doping Agency (WADA) has started a monitoring program targeting GLP-1 receptor agonists, as officials examine whether the medicines could be misused in professional sport. The drugs, widely linked to weight management, are currently permitted, but WADA said they remain under ongoing review.

WADA’s stated aim is to gather evidence that helps determine whether GLP-1 receptor agonists could satisfy the standards used to add substances to the prohibited list. Officials are looking at whether the drugs may boost performance, pose health risks to athletes, or run counter to the spirit of sport.

Weight-restricted sports and competitive fairness

The World Anti

A central focus is competitive integrity in disciplines where athletes must meet strict weight limits. Officials are assessing whether GLP-1 drugs could make it easier to reach a target weight, potentially creating an unfair advantage in weight-restricted sports such as boxing or wrestling. WADA’s review includes the possibility of what it described as “competitive manipulation” if evidence suggests that weight management through these medicines could influence outcomes. Officials said future restrictions could follow if monitoring and subsequent research support that assessment. Officials also pointed to an existing comparison within anti-doping rules. Diuretics are prohibited because they can be used to manipulate body weight and to conceal the use of other banned substances, and regulators are using that analogy as part of a forward-looking review of whether a similar approach could be warranted for GLP-1 drugs. Potential effects beyond weight loss, and the evidence gap

Beyond established uses in weight loss, emerging research has suggested additional physiological effects that are being discussed by officials and experts. Areas cited include improved metabolic health, reduced systemic inflammation, and better cardiovascular efficiency. Experts have argued that if such effects translate into better output, that could raise the likelihood of a reassessment under WADA’s criteria. At the same time, officials have emphasized that the evidence base remains limited in the context most relevant to anti-doping policy. A key uncertainty is that clinical studies have not yet assessed the direct impact of GLP-1 receptor agonists on elite, non-obese athletes. Officials have noted that findings in one population do not automatically apply to another, leaving unanswered questions about potential performance effects and health risks in top-level competition. How WADA says a decision would be made The discussion highlights a broader challenge for anti-doping authorities: how to address substances that can have legitimate therapeutic roles while also raising questions about competitive advantage. WADA said the monitoring program is intended to support a more evidence-based decision-making process.

Officials said any definitive classification decision would come after comprehensive analysis that weighs athlete welfare alongside fairness in competition. For now, GLP-1 receptor agonists remain allowed, while WADA uses the monitoring effort as an early-warning mechanism as regulators track their possible implications for sport.